Free Trial

Alzamend Neuro (ALZN) Competitors

Alzamend Neuro logo
$1.27 +0.01 (+0.79%)
As of 04:00 PM Eastern

ALZN vs. CVM, ATHE, CVKD, LVTX, PULM, INKT, LSTA, NKGN, ENLV, and LPCN

Should you be buying Alzamend Neuro stock or one of its competitors? The main competitors of Alzamend Neuro include CEL-SCI (CVM), Alterity Therapeutics (ATHE), Cadrenal Therapeutics (CVKD), LAVA Therapeutics (LVTX), Pulmatrix (PULM), MiNK Therapeutics (INKT), Lisata Therapeutics (LSTA), NKGen Biotech (NKGN), Enlivex Therapeutics (ENLV), and Lipocine (LPCN). These companies are all part of the "pharmaceutical products" industry.

Alzamend Neuro vs.

CEL-SCI (NYSE:CVM) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership, valuation and community ranking.

CEL-SCI has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500. Comparatively, Alzamend Neuro has a beta of -0.06, indicating that its stock price is 106% less volatile than the S&P 500.

Alzamend Neuro's return on equity of 0.00% beat CEL-SCI's return on equity.

Company Net Margins Return on Equity Return on Assets
CEL-SCIN/A -239.31% -102.69%
Alzamend Neuro N/A N/A -568.88%

Alzamend Neuro received 6 more outperform votes than CEL-SCI when rated by MarketBeat users. Likewise, 100.00% of users gave Alzamend Neuro an outperform vote while only 0.00% of users gave CEL-SCI an outperform vote.

CompanyUnderperformOutperform
CEL-SCIOutperform Votes
No Votes
Underperform Votes
10
100.00%
Alzamend NeuroOutperform Votes
6
100.00%
Underperform Votes
No Votes

12.1% of CEL-SCI shares are owned by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are owned by institutional investors. 16.2% of CEL-SCI shares are owned by company insiders. Comparatively, 10.6% of Alzamend Neuro shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Alzamend Neuro has a consensus target price of $32.00, indicating a potential upside of 2,439.68%. Given Alzamend Neuro's stronger consensus rating and higher probable upside, analysts plainly believe Alzamend Neuro is more favorable than CEL-SCI.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CEL-SCI
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Alzamend Neuro
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CEL-SCIN/AN/A-$32.19M-$0.58-0.74
Alzamend NeuroN/AN/A-$9.95MN/AN/A

In the previous week, Alzamend Neuro had 1 more articles in the media than CEL-SCI. MarketBeat recorded 5 mentions for Alzamend Neuro and 4 mentions for CEL-SCI. Alzamend Neuro's average media sentiment score of 1.88 beat CEL-SCI's score of 0.17 indicating that Alzamend Neuro is being referred to more favorably in the news media.

Company Overall Sentiment
CEL-SCI Neutral
Alzamend Neuro Very Positive

Summary

Alzamend Neuro beats CEL-SCI on 10 of the 13 factors compared between the two stocks.

Get Alzamend Neuro News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALZN vs. The Competition

MetricAlzamend NeuroPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$6.85M$6.64B$5.22B$9.05B
Dividend YieldN/A2.92%4.99%4.19%
P/E RatioN/A10.7888.0517.31
Price / SalesN/A201.161,103.55127.59
Price / CashN/A57.1143.2637.86
Price / Book-0.365.265.185.19
Net Income-$9.95M$153.48M$121.70M$226.98M
7 Day Performance5.00%5.66%4.64%3.22%
1 Month Performance10.53%0.22%21.59%4.45%
1 Year Performance-86.74%7.04%32.00%21.75%

Alzamend Neuro Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALZN
Alzamend Neuro
3.2084 of 5 stars
$1.27
+0.8%
$32.00
+2,419.7%
-86.7%$6.90MN/A0.004Positive News
Gap Up
CVM
CEL-SCI
N/A$0.41
-32.3%
N/A-81.7%$25.94MN/A-0.7043High Trading Volume
ATHE
Alterity Therapeutics
2.8153 of 5 stars
$3.50
+11.5%
$6.00
+71.4%
+99.1%$25.57MN/A0.0010Positive News
Gap Up
High Trading Volume
CVKD
Cadrenal Therapeutics
2.5869 of 5 stars
$14.23
-11.9%
$32.00
+124.9%
N/A$25.37MN/A-2.134Gap Down
LVTX
LAVA Therapeutics
2.8456 of 5 stars
$0.99
-0.3%
$3.33
+236.7%
-41.1%$25.10M$7.35M-0.9660
PULM
Pulmatrix
0.0495 of 5 stars
$6.86
+7.2%
N/A+246.2%$25.05M$10.01M-2.6020Analyst Forecast
News Coverage
INKT
MiNK Therapeutics
2.4428 of 5 stars
$0.63
+9.6%
$6.50
+931.7%
-14.7%$24.97MN/A-1.6230
LSTA
Lisata Therapeutics
2.4201 of 5 stars
$2.94
-2.6%
$15.00
+410.2%
+30.5%$24.68MN/A-1.1730Gap Up
NKGN
NKGen Biotech
N/A$0.70
-2.3%
N/A-75.0%$24.65M$80,000.00-0.14N/A
ENLV
Enlivex Therapeutics
2.619 of 5 stars
$1.15
-3.4%
$9.50
+726.1%
-65.5%$24.62MN/A-1.1770Gap Down
LPCN
Lipocine
1.4551 of 5 stars
$4.58
-3.8%
$10.00
+118.3%
+75.1%$24.49M$7.92M-6.0310Gap Up

Related Companies and Tools


This page (NASDAQ:ALZN) was last updated on 1/6/2025 by MarketBeat.com Staff
From Our Partners